| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Contineum Therapeutics, Inc. | Chief Scientific Officer | Class A Common Stock | 169K | $2.7M | $16.02 | Nov 25, 2024 | Direct |
| Contineum Therapeutics, Inc. | Chief Scientific Officer | Class A Common Stock | 3.9K | $62.4K | $16.02 | Nov 25, 2024 | By Spouse |
| Contineum Therapeutics, Inc. | Chief Scientific Officer | Stock Option (right to buy) | 110K | Jan 31, 2025 | Direct | ||
| Contineum Therapeutics, Inc. | Chief Scientific Officer | Stock Option (right to buy) | 3.7K | Jan 31, 2025 | By Spouse |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| CTNM | Contineum Therapeutics, Inc. | Jan 31, 2025 | 2 | $0 | 4 | Jan 31, 2025 | Chief Scientific Officer |
| CTNM | Contineum Therapeutics, Inc. | Nov 25, 2024 | 1 | -$16.2K | 4 | Nov 27, 2024 | Chief Scientific Officer |
| CTNM | Contineum Therapeutics, Inc. | Nov 18, 2024 | 2 | -$101K | 4 | Nov 20, 2024 | Chief Scientific Officer |
| CTNM | Contineum Therapeutics, Inc. | May 24, 2024 | 2 | $0 | 4 | May 29, 2024 | Chief Scientific Officer |
| CTNM | Contineum Therapeutics, Inc. | Apr 4, 2024 | 0 | $0 | 3 | Apr 4, 2024 | Chief Scientific Officer |